Spyre Therapeutics, Inc. (SYRE)
2025-06-30 | ||||
|---|---|---|---|---|
| Income tax benefit (expense) | - | |||
| Research and development | 40,145 | |||
| General and administrative | 11,790 | |||
| Gain on sale of in-process research and development asset | 10,000 | |||
| Total operating expenses | 41,935 | |||
| Loss from operations | -41,935 | |||
| Other (expense) income, net | -656 | |||
| Interest income | 5,874 | |||
| Total other income | 5,218 | |||
| Loss before income tax expense | -36,717 | |||
| Net loss | -327 | |||
| Net loss per share, basic (in dollars per share) | -19.62 | |||
| Net loss per share, diluted (in dollars per share) | -19.62 | |||
| Weighted-average common stock outstanding, basic (in shares) | 16,667 | |||
| Weighted-average common stock outstanding, diluted (in shares) | 16,667 | |||